Calendario›YARW›Experimental: YB-101
Experimental: YB-101
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Ensayo de Yarrow Bioscience, Inc. en Graves' Disease (del registro, en inglés).
- Fase
- Fase 2
- Estado
- Reclutando pacientes
- Participantes
- 232
- Centros
- 30
- Fin del objetivo primario
- dic 2027
previstos
estimado por el promotor
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, doble ciego. Comenzó en jun 2026.
Qué mide
Type and frequency of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) (del registro, en inglés) (inicio y dia 169)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body. The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2. Participants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.
Ficha completa en ClinicalTrials.gov (NCT07682896), actualizada en sep 2026.